BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:TSRA-196 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of TSRA-196\, from ClinicalTrials.gov estima
 tes.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07227207-11307@assetmemo.bio
DTSTAMP:20261121T004104Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:TSRA-196: Phase 1/2 readout est. (NCT07227207)
DESCRIPTION:TSRA-196\, phase 1/2\, Alpha-1 Antitrypsin Deficiency.\nStudy: 
 A Study of TSRA-196 in Adults With PiZZ Alpha-1 Antitrypsin Deficiency (AA
 TD)\nEstimated primary completion: March 2029. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/tsra-196#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07227207
URL:https://assetmemo.bio/drug/tsra-196#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
